Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers


ABSTRACT

Background Germline mutations in CDH1 are associated with hereditary diffuse gastric cancer; lobular breast cancer also occurs excessively in families with such condition.

Method To determine if CDH1 is a susceptibility gene for lobular breast cancer in women without a family history of diffuse gastric cancer, germline DNA was analysed for the presence of CDH1 mutations in 318 women with lobular breast cancer who were diagnosed before the age of 45 years or had a family history of breast cancer and were not known, or known not, to be carriers of germline mutations in BRCA1 or BRCA2.

Results No truncating mutations and no large deletions were detected. Six non-synonymous variants were found in seven families. Four (4/318 or 1.3%) are considered to be potentially pathogenic through in vitro and in silico analysis.

Conclusion Potentially pathogenic germline CDH1 mutations in women with early-onset or familial lobular breast cancer are at most infrequent.

INTRODUCTION

CDH1 encodes the cell–cell adhesion molecule, E-cadherin. Loss of expression of E-cadherin contributes to the infiltrative and metastatic behaviours of cancers. Germline loss-of-function mutations in CDH1 are associated with the autosomal dominant cancer-predisposition syndrome, hereditary diffuse gastric cancer (HDGC) (OMIM: +192090). In HDGC, germline mutations in CDH1 confer a high lifetime risk of DGC for male and female mutation carriers. Additionally, female mutation carriers have a 39%–52% lifetime risk of breast cancer, although these estimates have wide confidence intervals. Multiple reports have established the association of lobular breast cancer (LBC) with HDGC and germline mutations in CDH1.

Previously, we identified one carrier of a germline truncating CDH1 mutation among 23 women with LBC known not to carry germline BRCA1 and BRCA2 mutations. This case series included women diagnosed with LBC at a young age (≤ 45 years) and women diagnosed with LBC at any age with a family history of breast cancer but not of gastric cancer (1/25 or 4.3%). The same mutation was subsequently confirmed in a relative of the mutation carrier who also had LBC. This coincidence of CDH1 mutations and hereditary LBC led us to assess the prevalence of CDH1 mutations in a series of 318 women with early-onset LBC or a family history of breast cancer, consistent with hereditary LBC, ascertained through breast cancer registries and high-risk cancer genetic clinics (Breast Cancer Family Registry, the kConFab and a consortium of breast cancer genetics clinics in the United States and Spain).

MATERIALS AND METHODS

Patient accrual, preparation of DNA and CDH1 sequencing, deletion analysis, mutation validation, and protein structure and functional analyses are described in the online supplementary material.

RESULTS

Germline DNAs from 327 eligible patients with LBC were analysed for variants in CDH1, but for nine samples, several exons failed to amplify, yielding incomplete results. Sequence analysis for heterozygous variants in the 318 patients with complete results did not detect any protein-truncating mutations. Multiplex Ligation-dependent Probe Amplification analyses in 134 patients did not reveal any large deletions in CDH1.

We did find 10 patients with non-synonymous variants. One non-synonymous change, c.1774G→A, p.A592T, was found in two patients and is a known germline variant that is not associated with risk of familial breast cancer or HDGC. The variant, c.2494G→A, p.V832M, which had previously been identified in a patient with HDGC and was functionally characterised as a pathogenic mutation, was found in a woman who was diagnosed as having LBC at the age of 45 years and had a family history of ductal breast cancer in a sister and unspecified breast cancer in a maternal aunt. Segregation analysis has not yet been performed. The remaining non-synonymous variants were novel and did not appear in any
public databases. These variants were c.8C→G, p.P3R; c.1223C→T, p.A408V; c.1297G→A, p.D433N; c.1813A→G, p. R695G and c.88C→A, p.F50T, which were found in two patients not known to be related. There was no family history of gastric cancer for any of the patients who carried novel non-synonymous variants (table 1).

Nine unreported novel silent changes were identified: five synonymous variants in exons and four variants in introns. Two of these novel changes were found in more than one patient (data not shown).

We performed several tests to assess the likelihood that any of the non-synonymous variants resulted in a loss of normal function. Web-based software (Sorting Intolerant from Tolerant, SIFT) that predicts whether the amino acid change conferred by the non-synonymous variants resulted in a loss of normal function (data not shown).

The likely pathogenicities of the novel non-synonymous variants were further assessed by analysing the predicted effects of amino acid changes on the three-dimensional structure of E-cadherin. Because the coordinates of the three-dimensional structure of the ectodomain of E-cadherin were not available, we used the model of the closely related paralog, C-cadherin, to predict likely changes in the structure. One of the mutations, c.1223C→T, p.A408V, changes the alanine residue, which is well-conserved in this family of proteins, to bulkier valine and is located in calcium ion-binding extracellular domain 5. Surface modelling of the mutated protein indicated that this bulky valine could conceivably alter the binding pocket of one of three calcium ions that mediate homotypic cadherin domain interactions (Supplementary figure 1). Another mutation, c.1297G→A, p.D433N, was also found to be located in close proximity to this calcium-binding site (Supplementary figure 1).

To test this hypothesis, we expressed normal E-cadherin or each of the mutated versions of the protein in cells lacking endogenous E-cadherin. As seen in Supplementary figure 2, E-cadherin mutated with the c.8C→G, p.P3R variant did exhibit membrane localisation, indicating that protein localisation was not grossly affected by this variant. Additionally, the other novel non-synonymous variants also demonstrated membrane localisation (data not shown). However, because the levels at which we expressed E-cadherin were not physiological, it is possible that subtle effects of the mutations could have been missed.

Taking into account the in vitro and in silico analysis, four non-synonymous variants (c.8C→G, p.P3R; c.1223C→T, p.A408V; c.1297G→A, p.D433N and c.2494G→A, p.V832M) are considered potentially pathogenic (4/318 or 1.3%). If we only consider the subset of patients who have been tested and found to carry BRCA1 or BRCA2 mutations, the prevalence of potentially pathogenic variants is 1.6% (4/246).

**DISCUSSION**

Germline mutations in *CDH1* are associated with a substantially increased risk of LBC. This study found that the prevalence of potentially pathogenic *CDH1* variants is low in patients with early-onset or familial LBC who do not report a clear family history of breast cancer in whom potentially pathogenic variants were identified. There was no known family history of gastric cancer in these patients.

<table>
<thead>
<tr>
<th>Non-synonymous variant</th>
<th>Criteria 1 or 2</th>
<th>BRCA1/2 mutation status</th>
<th>Age at diagnosis</th>
<th>Family history (age at diagnosis)</th>
</tr>
</thead>
<tbody>
<tr>
<td>c.8C→G, p.P3R</td>
<td>1</td>
<td>Negative</td>
<td>38 years</td>
<td>Maternal aunt—breast cancer (46 years)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Maternal aunt—breast cancer (67 years)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Maternal cousin—breast cancer (42 years)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Mother—retropertioneal tumour</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Paternal grandmother—breast cancer</td>
</tr>
<tr>
<td>c.88C→A, p.P30T (two patients)</td>
<td>1</td>
<td>Unknown</td>
<td>40 years</td>
<td>Paternal aunt—breast cancer (40 years)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2</td>
<td>Negative</td>
<td>47 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Male paternal cousin—breast cancer (50 years)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Female paternal cousin—breast cancer (47 years)</td>
</tr>
<tr>
<td>c.1223C→T, p.A408V</td>
<td>1</td>
<td>Negative</td>
<td>44 years</td>
<td>No cancers</td>
</tr>
<tr>
<td>c.1297G→A, p.D433N</td>
<td>1</td>
<td>Negative</td>
<td>41 years</td>
<td>Paternal grandmother—intestinal cancer</td>
</tr>
<tr>
<td>c.1813A→G, p.R605G</td>
<td>1</td>
<td>Unknown</td>
<td>42 years</td>
<td>Maternal grandmother—lung cancer</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Maternal grandfather—mouth cancer</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Mother—breast cancer (60 years)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Maternal uncle—pancreatic cancer (64 years)</td>
</tr>
<tr>
<td>c.2494G→A, p.V832M (known missense mutation in HDGC)</td>
<td>1</td>
<td>Negative</td>
<td>43 years</td>
<td>Sister—ductal breast cancer</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Maternal aunt—breast cancer</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Paternal uncle—leukaemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Paternal grandmother—colon cancer</td>
</tr>
</tbody>
</table>

Clinical history of patients with LBC in whom potentially pathogenic variants were identified. There was no known family history of gastric cancer in these patients.
family history of DGC. The large sample size increases the likelihood that the results in this setting are precise. This study highlights the utility of publicly available registries as valuable resources of clinically and epidemiologically annotated families with accompanying germline DNA for future research in this field.

It remains possible that CDH1 mutations are present in rare families with multiple LBCs even without gastric cancer. Although the patients in the present study had confirmed LBC, we were unable to confirm the pathology of the breast cancers in the relatives, which remained unspecified for most of the patients. Additionally, because 72 patients (23%) were not tested for mutations in BRCA1 and BRCA2 (table 2), it is possible that some BRCA1 and BRCA2 mutation carriers were included in this study. The likelihood, however, is low because most early-onset and familial breast cancers are not accounted for by germline mutations in BRCA1 and BRCA2. We had previously reported a pathogenic truncating CDH1 mutation in a patient with LBC and her mother, who had both developed LBC before age 45 years. However, our data suggest that CDH1-associated LBC without gastric cancer must be very rare because so few were identified in the present study among women highly selected for early-onset LBC or LBC with additional breast cancer in the family. It might still be prudent to consider germline CDH1 testing in families with confirmed multiple cases of early-onset LBC, even in the absence of a family history of gastric cancer. In such families, and in those with a reported but unspecified history of abdominal cancer, the possibility of ovarian cancer would lead to BRCA1 and then BRCA2 testing, and the possibility of DGC should lead to consideration of CDH1 testing. For women with LBC, it is important to look for a family history of gastric cancer so that HDGC families will be recognised and offered appropriate management for their risk of DGC.

In our study, the pathogenic germline variant, p.V832M, was identified in a patient with LBC without a family history of gastric cancer. This variant was initially found to segregate with disease in a Japanese family where the proband had DGC at age 61 years and four of seven siblings, the mother and a niece all had unspecified gastric cancer. Functional characterisation in Chinese hamster ovary cells demonstrated reduced cell aggregation and increased invasive properties of the mutant compared with wild-type E-cadherin. Although this effect was not reproduced in functional characterisation undertaken in human squamous epithelial cells, further work has demonstrated a mechanism by which this mutation might confer a pathogenic effect, through loss of type 1Y phosphatidylinositol phosphate kinase binding, causing abnormal E-cadherin trafficking and adherens junction formation.

The novel non-synonymous variants in this study were not confirmed by our in vitro and in silico studies to be pathogenic, although further investigation needs to be done on the suggestive evidence that the variants c.1223C>T, p.A408V and c.1297G>A, p.D433N might interfere with calcium-dependent homophilic binding. Also, a novel, presumably rare variant (c.88 C>A, p.F30T) was shared by two patients with LBC from one of the high-risk breast cancer clinics: this could imply that this variant is linked to the disease and that these two women are distantly related. Alternatively, this may represent a rare variant not associated with LBC, whose distribution in the normal population frequency will become known as the genomes of more people are sequenced. Data from the 1000 Genomes Project may also be helpful in the interpretation of the significance of these variants, through demonstration of the full profile of

| Table 2. Criteria for ascertainment for CDH1 mutation analysis |
|------------------------|------------------------|------------------------|------------------------|
| Breast Cancer Genetics Consortium (n=120) | Breast Cancer Genetics Consortium (n=165) | Breast Cancer Genetics Consortium (n=33) |
| Criteria 1 | Criteria 2 | Criteria 1 | Criteria 2 | Criteria 1 | Criteria 2 |
| Sex | F | F | F | F | F |
| Median age (years) | 40 | 54 | 40 | 54 | 40 | 54 |
| Age range (years) | 28-49 | 45-70 | 28-49 | 45-70 | 28-49 | 45-70 |
| Novel non-synonymous variants in criteria | 15 | 23 | 142 | 27 | 142 | 27 |
| BRCA1/2 negative (n=66) | 61 | 0 | 51 | 0 | 51 | 0 |
| BRCA1/2 unknown (n=64) | 6 | 0 | 8 | 0 | 8 | 0 |
normal variation within CDH1 and their distribution in and across populations. Although a combination of LBC and DGC is strongly indicative of germline mutations in CDH1, in the absence of a history of DGC, CDH1 mutations appear to be extremely rare. It is possible that CDH1 mutations would be more often identified in families with multiple documented invasive lobular or mixed ductal/lobular breast cancers in the absence of DGC, but such families are uncommon. Therefore, a history of early-onset or familial LBC should trigger specific questions around a history of abdominal cancer.

Author affiliations
1Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada
2Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
3Hereditary Program, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
4Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
5Memorial Sloan–Kettering Cancer Center, New York, New York, USA
6Massachusetts General Hospital, Boston, Massachusetts, USA
7University of Chicago Medical Center, Chicago, Illinois, USA
8Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA
9Stanford University School of Medicine, Stanford, California, USA
10Lambardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA
11Breast Center, Baylor College of Medicine, Houston, Texas, USA
12Hospital Vall d’Hebron, Barcelona, Spain
13Department of Cancer Biology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
14Columbia University, New York, New York, USA
15Northern California Cancer Prevention Institute, California, Fremont, California, USA
16Ontario Cancer Genetics Network, Cancer Care Ontario, Fred A. Litwin Center for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada
17Division of Epidemiology and Biostatistics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
18University of Toronto and St Michael’s Hospital, Toronto, Ontario, Canada
19Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
20National Institutes of Health, Bethesda, Maryland, USA
21The Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia
22Genome Sciences Centre, Vancouver, BC, Canada
23Department of Pathology, University of Melbourne, Melbourne, Victoria, Australia
24Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, University of Melbourne, Victoria, Australia

Acknowledgements
Samples from the Fox Chase Cancer Center, Huntsman Cancer Institute and Northern California Cancer Center were processed and distributed by the Coriell Cell Repositories through cooperative agreements. The content of this article does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centres in the Breast CFR, nor does mention of trade names, commercial products or organizations imply endorsement by the US government or the Breast CFR. The authors thank Heather Thorne, Eveline Niedermayer, all the kConFab research nurses and staff, and the heads and staff of the Family Cancer Clinics and the clinical follow-up study (funded by NHMRC grants 145684, 286704 and 455408) for their contributions to this resource and the many families who contribute to kConFab. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic healthcare centres, the National Center for Research Resources or the National Institutes of Health. The authors would like to acknowledge Kenneth Offit and Lisa Ballestri (Memorial Sloan–Kettering Cancer Center), Katherine L. Nathanson (University of Pennsylvania), Nick Chun, Kerry Kingham and Meredith Mills (Stanford University), Vanessa Sern and Katherine Corso (Dana Farber Cancer Institute), Pat Devanshi (Massachusetts General Hospital) and the Niehaus, Southworth, Weissenbach Cancer Research Initiative, the Lymphoma Foundation and the Sabin Family Cancer Research Initiative.

Funding
The collection of resources from the Breast CFR was supported by the National Cancer Institute, National Institutes of Health under RFA-CA-06-503 and through cooperative agreements with members of the Breast Cancer Family Registry (CFR) and principal investigators including those from Cancer Care Ontario (U01 DA69467), Columbia University (U01 CA69538), Fox Chase Cancer Center (U01 CA69361), the Northern California Cancer Center (U01 DA69417), the University of Melbourne (U01 CA69638) and Research Triangle Institute Informatics Support Center (RFP No. N2CP45022-46). kConFab is supported by grants from the National Breast Cancer Foundation and the National Health and Medical Research Council and by the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia. The Breast Cancer Genetics Consortium was funded by a Breast Cancer Research Foundation grant to JG and the consortium (Dana Farber Cancer Institute, Beth Israel Deaconess Medical Center, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, University of Chicago, University of Pennsylvania, Stanford University, Georgetown University, Baylor College of Medicine and Hospital in Fall (D’Hebron)). DNA and mutation analysis was performed at the Huntsman Laboratory, British Columbia Cancer Agency and the Genome Sciences Centre, and was supported by the Canadian Cancer Society (principal investigator: David Huntsman; grant No. 183811). This research was supported in part by the Dana Farber/Harvard Cancer Center Breast SPORE (grant number: NIH/NCI (P50-CA89393)). KAS is supported by the University of British Columbia’s Clinician Investigator Program. DNS is supported by a Cancer Institute NSW fellowship. SM was supported by Charles A. King Trust, Bank of America Fellowship, Co-Trustee (Boston, MA) and The Humane Society of the Commonwealth of Massachusetts Postdoctoral Research Fellowship. This work was conducted with support from the Scholars in Clinical Science Program of Harvard Catalyst, The Harvard Clinical and Translational Science Center [award No. UL1 RR 025756] and with financial contributions from Harvard University and its affiliated academic healthcare centres.

Competing interests None declared.

Ethics approval Not commissioned; externally peer reviewed.

REFERENCES


SUPPLEMENTARY MATERIALS AND METHODS:

Patient accrual:

327 LBC cases were identified through three different sources. The Breast Cancer Family Registry (Breast CFR) is an NCI-sponsored resource, which includes six population-based and clinic-based family registries and a collection of samples and data from more than 12,500 families with and without breast cancer [1]. Samples (n=168) were obtained from the Northern California, New York, Australia, Philadelphia, and Ontario sites of the Breast CFR. The Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab) provided specimens (n=33) from families with a strong history of breast cancer, recruited from family cancer clinics in Australia and New Zealand [2]. The 126 remaining samples were collected through a Breast Cancer Research Foundation (BCRF)-funded Breast Cancer Genetics Consortium, a group of high-risk cancer clinics which included Dana-Farber Cancer Institute, Baylor College of Medicine, Beth Israel Deaconess Medical Center, Georgetown University, Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, Stanford University, the University of Chicago, the University of Pennsylvania, and the Hospital Vall d'Hebron, Barcelona, Spain. The inclusion criteria for the identification of the eligible LBC cases differed slightly between these groups. For cases from the Breast CFR and kConFab, eligibility for this study required a female case with documented invasive lobular or mixed (lobular and ductal) breast cancer, not known to carry germline BRCA1 and BRCA2 mutations, and either: (1) diagnosed before age 45 years, or (2) at any age but with two or more cases of breast cancer in first- or second-degree relatives. For cases from the BCRF-funded Breast Cancer Genetics Consortium, eligible women had a
diagnosis of invasive lobular or mixed (lobular and ductal) breast cancer, were not known to carry germline \textit{BRCA1} and \textit{BRCA2} mutations, and were either: (1) diagnosed before age 45 years, or (2) diagnosed at any age but with at least two or more cases of breast cancer in first- or second-degree relatives, and third-degree relatives in the paternal lineage, and with no reported family history of gastric cancer. The characteristics of the LBC cases screened for mutations in \textit{CDH1} are summarized in Table 1. All cases had provided written informed consent and the study protocols were approved by the institutional review board at each participating center. DNA was extracted at the molecular laboratories for some of the collaborating centers using standard procedures (Qiamp DNA Blood Midi kit; Qiagen, Valencia, CA, USA) and anonymized genomic DNA samples were sent to the Centre for Translational and Applied Genomics (CTAG) at the British Columbia Cancer Agency (BCCA) where the analysis of \textit{CDH1} was performed (Table 1).

\textbf{Preparation of DNA and \textit{CDH1} sequencing:}

To accommodate the limited amount of DNA available, genomic DNA samples were subjected to whole-genome amplification using the GenomiPhi DNA amplification kit (GE Healthcare Bio-Sciences Inc., Quebec, Canada) as performed in our earlier study [3]. Exons and intron-exon boundary splice junctions of half the study cohort were amplified and screened for heterozygous base changes by the denaturing high pressure liquid chromatography (DHPLC) [3]. The primer sequences and conditions used have previously been described [4]. Exons displaying DHPLC changes consistent with a heterozygous variation were reamplified and PCR products were purified (Qiagen
MinElute; Qiagen, Mississauga, ON). Bidirectional sequencing was then performed (Big Dye Terminator V.3.1 Cycle Sequencing Kit; Applied Biosystems, Foster City, California, USA) and analysed (ABI Prism 310 Genetic Analyzer). Germline mutations in CDH1 appear as heterozygous sequence changes, with the exception of large deletions, which are not detected by sequencing. Sequencing of all exons and intron-exon boundaries were carried out on the remaining samples using validated primer sets [5], at the Genome Sciences Centre on a service basis or in our laboratory.

**Deletion Analysis:**

Multiplex Ligation-dependant Probe Amplification (MLPA), previously used to identify large-scale deletions in CDH1, has been described previously [6]. MLPA could only be performed on 134 samples for which sufficient germline DNA was available.

**Mutation Validation:**

Basic Local Alignment Search Tool (http://blast.ncbi.nlm.nih.gov/Blast.cgi) was used to compare sample sequences to the NCBI cDNA NM_004360.3 and the genomic DNA NG_008021.1, GI:190341080. Web-based software programs were used to look for predicted effects on splicing (Splice Site Prediction by Neural Network hosted by the Berkeley Drosophila Genome Project) and the predicted effects of amino acid changes on protein structure (Sorting Intolerant From Tolerant, SIFT, software version 2, Fred Hutchinson Cancer Research Center, Seattle, Wash).

**Protein structure analysis:**
Protein structure analysis and preparation of structural models was performed using the PyMol software package (DeLano Scientific). Structural co-ordinates were obtained from X-ray crystal structures of the ectodomain of C-cadherin (PDB code 1L3W) [7].

**Functional Characterization:**

**Site directed mutagenesis:**

To examine the effects of the missense mutations on protein localization, wild-type E-cadherin-WTpcDNA3.1 plasmids [8] were mutated using QuickChange site-directed mutagenesis kit (Stratagene, Cedar Creek, Texas) as per the manufacturer’s instructions to create each of the novel non-synonymous variants we identified. The corresponding forward primer sequences are included following each variant: c.1223C>T, A408V, 5’-CCCCAATACCCCCAGTGGGGAGGCTGTAT-3’; c.8C>G, P3R, 5’-CTTACCATGGCCGTTTGGAGCCGCAGC-3’; c.88 C>A, P30T, 5’-GGAGCCCTGGCCACACTGGCTTTGACGC-3’; c.88 C>A, P30T, 5’-GGAGCCCTGGCCACACTGGCTTTGACGC-3’; c.1813A>G, 5’-ACTATATTCTTCTGTGAGGGGAATCCAAAGCCTCAGG-3’; c.1297G>A, D433N, 5’-CCACAAATCCAGTGGAACAAATGGCATTGGAAACAGCA-3’). The mutated plasmids were validated by DNA-sequencing.

**Cell culture:**

The immortalized ovarian surface epithelial cell-line, IOSE-80pc, that does not express E-cadherin [9] and the ovarian carcinoma cell line, OVCAR-3, that highly expresses E-cadherin [9], were maintained in a 1:1 mixture of MCDB 105 medium and Medium 199
(Sigma, St. Louis, MO, USA), supplemented with 5% fetal bovine serum (FBS) (Gibco BRL).

**Transient transfections:**

Aliquots of IOSE-80pc cells were transfected in parallel with the E-cadherin variants under investigation; c.1223C>T, A408V; c.8C>G, P3R; c.88 C>A, P30T; c.1813A>G, R695G; c.1297G>A, D433N and control plasmids. These controls included the empty vector LacZ as a control for the transfection procedure, wild-type (wt) E-cadherin and known loss of function E-cadherin mutants (c.1018A>G and c.2494G>A) that cause HDGC. Transient transfections were performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the manufacturer’s guidelines.

**Fluorescence microscopy:**

E-cadherin staining was performed on subconfluent cell monolayers cultured on glass coverslips. Cells were washed once in media alone and then fixed in 4% paraformaldehyde (PFA) for 20 minutes at room temperature. Cells were washed with phosphate-buffered saline (PBS) before and after permeabilization with 0.2% Triton X-100 for 10 min at room temperature. To decrease non-specific background, cells were incubated with serum-free protein block (Dako, Carpinteria, CA) for 30 minutes prior to incubation with a mouse monoclonal antibody [1:500] to the extracellular domain (HECD-1, 205601 Calbiochem) at room temperature. Primary antibody was detected using Alexa Fluor 488 goat anti-mouse IgG (Invitrogen, Carlsbad, CA) [1:500] for 60 minutes at room temperature. Cells were counterstained with DAPI [1:1000] prior to
mounting with glycerol. Slides were analyzed using the Axioplan 2, Zeiss (MetaSystems, Isis) camera VAC-30054 and pictures were obtained at 40x magnification.

References


